Labetuzumab
NY (what is this?) (verify) Tumor
Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer.[1] It selectively binds to carcinoembryonic cell adhesion molecule 5. [2]
Also tried in patients with MTC (medullary thyroid carcinoma) with metastasis.
This drug was developed by Immunomedics, Inc.
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN): Labetuzumab" (PDF). WHO Drug Information. 16 (1): 95. 2002.
- ^ "labetuzumab-SN-38 immunoconjugate IMMU-130". National Cancer Institute: NCI Dictionaries. National Institutes of Health, U.S. Department of Health and Human Services.
- v
- t
- e
Monoclonal antibodies for tumors
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e